They Are People First, Then Patients

Sponsored by Libo Pharma (Asia, Oceania)

SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF NM-IL-12 (rHuIL‐12) IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B- CELL LYMPHOMA (DLBCL) UNDERGOING SALVAGE CHEMOTHERAPY